Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
20 hedge funds and large institutions have $91.5M invested in Kindred Biosciences, Inc. in 2013 Q4 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$34.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.1M |
| 4 |
Jennison Associates
New York
|
+$10.7M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$7.15M |
Top Sellers
KIN Hedge Fund Activity: Q4 2013 in Review
20 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q4 2013, worth a combined $91.5M.
Buyers outnumbered sellers: 20 funds opened new KIN positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baupost Group, opening a new position worth an estimated $34.6M.
- 20 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $91.5M of Kindred Biosciences, Inc. stock for Q4 2013.
- 20 funds opened new Kindred Biosciences, Inc. positions in Q4 2013 and 0 closed out, a net change of +20 holders.
- The largest Kindred Biosciences, Inc. buyer in Q4 2013 was Baupost Group, an estimated $34.6M added.
Based on aggregated 13F filings for Q4 2013.